Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US

References

• International Agency for Research on Cancer, Cancer Research UK. World cancer factsheet. 2014. Available at: http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_WORLD.pdf [Last accessed 21 May 2015]
   Google Scholar
• National Cancer Institute. SEER Cancer Statistics Factsheets: Breast Cancer. 2014. Available at: http://seer.cancer.gov/statfacts/html/breast.html [Last accessed 17 September 2015]
   Google Scholar
• Dawood S, Broglio K, Ensor J, et al. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010;21(11):2169-74
   Google Scholar
• Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Breast Cancer Version 3.2015. 2015:1-187. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [Last accessed 17 September 2015]
   Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870-84
   PubMed Web of Science ®Google Scholar
• Ray S, Bonthapally V, McMorrow D, et al. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. J Comp Eff Res 2013;2:195-206
   PubMed Web of Science ®Google Scholar
• DeKoven M, Bonthapally V, Jiao X, et al. Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res 2012;1:453-63
   PubMed Web of Science ®Google Scholar
• Macalalad AR, Hao Y, Lin PL, et al. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010). Curr Med Res Opin 2015;31:263-73
   PubMed Web of Science ®Google Scholar
• Andre F, Neven P, Marinsek N, et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin 2014;30:1007-16
   PubMed Web of Science ®Google Scholar
• Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006; 11(Suppl 1):42-51
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang H, Wei JF, Meng L. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials. Curr Med Res Opin 2012;28:1911-19
   PubMed Web of Science ®Google Scholar
• Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2012;136: 777-88
   PubMed Web of Science ®Google Scholar
• Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003;8:514-20
   PubMed Web of Science ®Google Scholar
• Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29:2144-9
   PubMed Web of Science ®Google Scholar
• Li N, Hao Y, Xie J, et al. Everolimus-based therapy versus chemotherapy among patients with HR+/HER2- metastatic breast cancer: comparative effectiveness from a chart review study. Int J Breast Cancer 2015;2015: 240750
   PubMedGoogle Scholar
• Xie J, Hao Y, Li N, et al. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin 2015:31(6):1095-103
   Google Scholar
• Cope S, Zhang J, Saletan S, et al. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med 2014;12:93
   PubMed Web of Science ®Google Scholar
• Generali D, Venturini S, Rognoni C, et al. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2015;152:95-117
   PubMed Web of Science ®Google Scholar
• Fasching PA, Decker T, Schneeweis A, et al. Breast cancer treatment with everolimus and exemestane for ER+ women – results of the 2nd interim analysis of the non-interventional trial BRAWO. J Clin Oncol 2014;32: (5s Suppl):abstr 578
   Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin 2014;30: 1537-45
   PubMed Web of Science ®Google Scholar
• Whyte JL, Engel-Nitz NM, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care 2015;53:e49-57
   PubMed Web of Science ®Google Scholar
• Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014;32:3307-29
   PubMed Web of Science ®Google Scholar
• Weide R, Mergenthaler U, Pandorf A, et al. Improved survival of patients with metastatic breast cancer in routine care: results of a retrospective study in a community-based oncology group practice 1995–2005. Onkologie 2009; 32:107-13
   PubMedGoogle Scholar
• Jung SY, Rosenzweig M, Sereika SM, et al. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 2012;23: 103-12
   PubMed Web of Science ®Google Scholar
• Bergh J, Jonsson PE, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40:253-81
   PubMed Web of Science ®Google Scholar
• Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-68
   PubMed Web of Science ®Google Scholar
• Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003;2:CD002747
   PubMedGoogle Scholar
• O'Malley KJ, Cook KF, Price MD, et al. Measuring diagnoses: ICD code accuracy. Health Serv Res 2005;40(5 Pt 2):1620-39
   Web of Science ®Google Scholar
• Peabody JW, Luck J, Jain S, et al. Assessing the accuracy of administrative data in health information systems. Med Care 2004;42:1066-72
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Jerusalem G, Hurvitz S, et al. BOLERO-6: phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+, HER2- advanced breast cance. J Clin Oncol 2013;31(suppl):abstr TPS660
   Google Scholar